TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae117 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Rita Abi-Raad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yale University School of Medicine, New Haven, CT, US. Hauptthemen laut MEDLINE: Telomerase, Thyroid Neoplasms, Promoter Regions, Genetic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Objectives
TERT promoter mutations are not infrequently encountered in thyroid carcinomas; however, it is unclear if additional molecular alterations may play a role in determining tumor behavior.
Methods
Fine-needle aspiration (FNA) specimens from 32 patients with TERT promoter mutations detected by ThyroSeq v3 from 4 institutions were included in the study. FNA diagnoses, molecular results, and surgical follow-up were retrospectively reviewed and analyzed.
Results
There were 5 benign and 27 malignant neoplasms, including 7 high-grade thyroid carcinomas (HGCs) on histopathologic follow-up. Of 4 cases with an isolated TERT mutation, 3 (75%) cases were malignant. Of 17 cases harboring a co-occurring TERT mutation with 1 additional molecular alteration, 13 (76%) displayed malignancy on histopathologic follow-up. All 11 cases with TERT mutations plus 2 or more additional molecular alterations were malignant on follow-up. Furthermore, HGC was not seen in cases with an isolated TERT mutation, while 80% of cases harboring TERT mutations plus 3 additional molecular alterations showed HGC.
Conclusions
TERT promoter mutations are commonly associated with malignancy, particularly HGCs, when multiple co-occurring molecular alterations are present. However, TERT promoter mutations may occasionally be detected in benign thyroid neoplasms when encountered in isolation or with fewer than 2 additional molecular alterations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Yale University School of Medicine, New Haven, CT, US.
- Department of Pathology, Emory University Hospital, Atlanta, GA, US.
- Department of Pathology, New York University Langone Health, New York, NY, US.
- Department of Pathology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, US.
- Department of Pathology and Laboratory Medicine, Dartmouth Health and Geisel School of Medicine at Dartmouth, Lebanon, NH, US.
- Yale Cancer Center, Yale University School of Medicine, New Haven, CT, US.
ORCID-Profile: Rita Abi-Raad, Fei Chen
Zitieren
APA
Abi-Raad, R., Shi, Q., Chen, F., Antony, V., Hsiao, W. Y., Simsir, A., Liu, X., Brandler, T. C., & Cai, G. (2025). TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae117
Vancouver
Abi-Raad R, Shi Q, Chen F, Antony V, Hsiao WY, Simsir A, et al. TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae117
BibTeX
@article{AbiRaad2025,
author = {Abi-Raad, Rita and Shi, Qiuying and Chen, Fei and Antony, Vijay and Hsiao, Wen-Yu and Simsir, Aylin and Liu, Xiaoying and Brandler, Tamar C and Cai, Guoping},
title = {TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae117}
}
EUVIMED